Aggrenox

Aggrenox is a brand name of aspirin/dipyridamole, approved by the FDA in the following formulation(s):

AGGRENOX (aspirin; dipyridamole - capsule, extended release; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: November 22, 1999
  
  Strength(s): 25MG;200MG ^[RLD][AB]

Has a generic version of Aggrenox been approved?

A generic version of Aggrenox has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Aggrenox and have been approved by the FDA:

ASPIRIN AND DIPYRIDAMOLE (aspirin; dipyridamole capsule, extended release; oral)

• 
  Manufacturer: BARR
  
  Approval date: August 14, 2009
  
  Strength(s): 25MG;200MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aggrenox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation
  Patent 6,015,577
  Issued: January 18, 2000
  Inventor(s): Eisert; Wolfgang & Gruber; Peter
  Assignee(s): Thomae GmbH; Dr. Karl
  The specification describes a pharmaceutical combination consisting of dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing this pharmaceutical combination and the use thereof for the controlled prevention of clot formation.
  
  Patent expiration dates:
  
  
  • January 18, 2017
    
    ✓ 
    Patent use: TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
  
  

See also...

• Aggrenox Consumer Information (Drugs.com)
• Aggrenox Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Aggrenox Consumer Information (Cerner Multum)
• Aggrenox Advanced Consumer Information (Micromedex)
• Aspirin/Dipyridamole Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Aspirin and dipyridamole Consumer Information (Cerner Multum)
• Aspirin and dipyridamole Advanced Consumer Information (Micromedex)